Navigation Links
SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
Date:6/9/2008

SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership for the Italian market through Medimar Italia, a Milan-based firm specializing in medical device sales in the country.

Michel Vaudry, SpectraScience's Director of International Sales commented that, "We are pleased to have added our second European distributor in the past two months. Medimar is a respected and well-established medical device distributor and its decision to add the WavSTAT Optical Biopsy System to their portfolio is a strong validation of our technology."

Medimar's President, Francesco Torelli, stated that, "SpectraScience's WavSTAT cancer diagnosis system has tremendous potential to impact the marketplace here in Italy. The importance of earlier and more effective screening for colon cancer cannot be stressed enough and we look forward to representing the product and working with SpectraScience to establish and build a strong Italian market presence."

Vaudry added that, "Mr. Torelli is a respected thought leader in the medical device market in Italy, so his support of the WavSTAT System will be instrumental in our acceptance into the major gastroenterology centers in the country."
Key Benefits to the WavSTAT Optical Biopsy System

-- Helps the physician discern between normal and pre-cancerous tissue in

the GI tract

-- Gives the physician additional information that allows for a more

informed decision on leaving polyps on site if they are not

pre-cancerous thereby minimizing risks and time.

-- Provides the opportunity for physicians to perform a physical biopsy at

exactly the same site and time that the optical biopsy is performed

-- Allows physicians to determine the margin, or border of the

pre-cancerous tissue

-- Aids physicians during colon cancer surgery to determine if all

cancerous tissue has been removed

-- Is complementary to NBI and Smart Pill and other recent evaluating

technologies (e.g. Olympus, Pentax, Fujinon, Given).

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

http://www.spectrascience.com

Hayden Communications

Investor Relations

Todd Pitcher

(858) 518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
6. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
7. UI licensee Optherion secures $37 million in financing
8. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
9. Piedmont Pharmaceuticals Secures $8.5 Million Investment
10. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
11. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... to and which He does not. Yisrayl says with so many titles and names ... name, but he says with a little Scripture, backed with a lot of research, the ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: